Ascendis Pharma AS (STU:A710)
€ 220 (0%) Market Cap: 14.51 Bil Enterprise Value: 14.83 Bil PE Ratio: 29.67 PB Ratio: 27.64 GF Score: 22/100

Ascendis Pharma A/S at JPMorgan Healthcare Conference Transcript

Jan 12, 2026 / 03:30PM GMT
Jessica Fye
JPMorgan Chase & Co - Analyst

Great, good morning. Welcome everyone, I'm Jess Fye, a biotech analyst at JPMorgan. We're so excited to be starting the 44th Annual JPMorgan Healthcare Conference this week with Ascendis.

The company's CEO, Jan Mikkelsen, is going to give a presentation, that's going to be followed by some Q&A. But first, it looks like I'm going to pass it over to Scott Smith, the CFO, for a forward-looking statement.

Scott Smith;S;Executive Vice President and Chief Financial Officer
Ascendis Pharma A

/-

Thanks a lot, Jess. It's my honor to read the first FLS of the year for Ascendis Pharma. Before we begin, I would like to remind you that this conference call will contain forward-looking statements that are intended to be covered under the safe harbor provided by the Private Securities Litigation Reform Act.

Examples of such statements may include, but are not limited to, statements regarding our commercialization, continued development of SKYTROFA and YORVIPATH as well as

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot